1208130-64-6

Basic information

• Product Name: N-((S)-1-((S)-1-(hydroxyamino)-5-(3-nitroguanidino)-1-oxopentan-2-ylamino)-1-oxopropan-2-yl)-4-methoxybenzamide
• Synonyms: N-((S)-1-((S)-1-(hydroxyamino)-5-(3-nitroguanidino)-1-oxopentan-2-ylamino)-1-oxopropan-2-yl)-4-methoxybenzamide
• CAS NO: 1208130-64-6
• Molecular Weight: 439.428
• Mol File: 1208130-64-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: N-((S)-1-((S)-1-(hydroxyamino)-5-(3-nitroguanidino)-1-oxopentan-2-ylamino)-1-oxopropan-2-yl)-4-methoxybenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-((S)-1-((S)-1-(hydroxyamino)-5-(3-nitroguanidino)-1-oxopentan-2-ylamino)-1-oxopropan-2-yl)-4-methoxybenzamide(1208130-64-6)
• EPA Substance Registry System: N-((S)-1-((S)-1-(hydroxyamino)-5-(3-nitroguanidino)-1-oxopentan-2-ylamino)-1-oxopropan-2-yl)-4-methoxybenzamide(1208130-64-6)

Safety Data

• Hazardous Substances Data: 1208130-64-6(Hazardous Substances Data)

Upstream product

• 74-79-3 L-arginine 
• 2149-70-4 N-nitro-L-arginine 
• 51298-62-5 nitro-L-arginine methyl ester hydrochloride 
• 93709-64-9 (S)-2-(4-methoxybenzamido) propanoic acid 
• 125700-05-2 (S)-methyl (4-methoxybenzoyl)alaninate 
• 1208130-72-6 (S)-methyl 2-((S)-2-(4-methoxybenzamido)propanamido)-5-(3-nitroguanidino) pentanoate 

Relevant articles and documents

Novel L-arginine derivatives as aminopeptidase N inhibitors: design, chemistry, and pharmacological evaluation

Considering the important roles played in tumor, aminopeptidase N has been an appealing target for anti-tumor drug development. Here, a serial of novel aminopeptidase N inhibitors with L-arginine scaffold were designed, synthesized and evaluated for aminopeptidase N inhibitory activities. The preliminary anti-enzyme activity assay demonstrated that compounds 5e, 5h, 11e, 11g, and 11h showed comparable activities with the positive control bestatin, an approved aminopeptidase N inhibitor. In vitro anti-proliferation assay, compound 5f showed excellent activities against four kinds of tumor cells which overexpress aminopeptidase N. In vivo anti-metastasis assay, compounds 5f and 11g exhibited better activities than bestatin. So 5f and 11g should be lead compounds as novel aminopeptidase N inhibitors for further development.